Skip to content


  • Research article
  • Open Access

Brain transcriptional stability upon prion protein-encoding gene invalidation in zygotic or adult mouse

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 2, 3,
  • 2,
  • 2,
  • 1,
  • 4,
  • 1,
  • 5,
  • 2,
  • 1,
  • 5 and
  • 1Email author
BMC Genomics201011:448

  • Received: 28 January 2010
  • Accepted: 22 July 2010
  • Published:



The physiological function of the prion protein remains largely elusive while its key role in prion infection has been expansively documented. To potentially assess this conundrum, we performed a comparative transcriptomic analysis of the brain of wild-type mice with that of transgenic mice invalidated at this locus either at the zygotic or at the adult stages.


Only subtle transcriptomic differences resulting from the Prnp knockout could be evidenced, beside Prnp itself, in the analyzed adult brains following microarray analysis of 24 109 mouse genes and QPCR assessment of some of the putatively marginally modulated loci. When performed at the adult stage, neuronal Prnp disruption appeared to sequentially induce a response to an oxidative stress and a remodeling of the nervous system. However, these events involved only a limited number of genes, expression levels of which were only slightly modified and not always confirmed by RT-qPCR. If not, the qPCR obtained data suggested even less pronounced differences.


These results suggest that the physiological function of PrP is redundant at the adult stage or important for only a small subset of the brain cell population under classical breeding conditions. Following its early reported embryonic developmental regulation, this lack of response could also imply that PrP has a more detrimental role during mouse embryogenesis and that potential transient compensatory mechanisms have to be searched for at the time this locus becomes transcriptionally activated.


  • Tg37 Mouse
  • Scrapie
  • Prnp Gene
  • Brain Transcriptome
  • Ifitm Gene


The pivotal role that the prion protein (PrP) plays in transmissible spongiform encephalopathies (TSE) is now well established [[1, 2] for recent reviews]. The conversion of this host-encoded protein to an abnormal, partially proteinase K resistant, isoform is a hallmark of most TSEs and PrP is the only known constituent of mammalian prions [3]. The Prnp gene that encodes for PrP, is expressed in a broad range of vertebrate tissues but most abundantly in the central nervous system [4].

Although PrP is evolutionary conserved, suggesting that it has an important role, its physiological function remains unclear even though its implication in neuroprotection, response to oxidative stress, cell proliferation and differentiation, synaptic function and signal transduction has been proposed [5, 6]. Its temporal regulation led also to suspect an implication of this protein in early embryogenesis [79] but Prnp-knockout mice [10, 11], cattle [12] and goat [13] were obtained with no drastic developmental phenotype and only subtle alterations of their circadian rhythm, hippocampal function and of their behavior. A similar observation was made when this gene was invalidated in adult neurons [14, 15]. To explain these data, it was hypothesized that another host-encoded protein is able to compensate for the lack of PrP [16]. However, this protein has not yet been identified.

Transcriptomic analysis has emerged as a powerful tool to decipher cellular pathways that are modified following a gene expression alteration as it does not pre-require the need of restricting hypothesis. Such approaches have been conducted to analyze the mechanisms underlying prion replication and neurotoxicity [see [1724] for recent examples]. The obtained results appeared however inconsistent and closely related to the cell type and/or strain and animal model used, leading to difficulties in identifying the metabolic pathways involved.

Fewer studies have used a similar approach to try to understand the biological function of the PrP protein in immortalized non-neuronal cells [2527]. The obtained results appear again to correlate with the cell line used as experimental model and no shared pathway has emerged from the comparison of these different experiments. In parallel, proteomic studies have been conducted either using two cell lines [28] or transgenic knockout mice [29]. While different sets of proteins were found to be affected by the PrP expression level in cells according to their origin, no significant difference was detected in the brain proteome of the analyzed 129/Sv-C57/Bl6 transgenic mice, bearing in mind that variations occurring for low abundant proteins might not have been detected [29].

In the present study, we report the comparisons of the whole brain transcriptomes of PrP knockout or wild type mice, both on an FVB/N genetic background, and of that of mice invalidated for the Prnp locus in adult neurons.

Results and Discussion

Comparative transcriptional analysis of FVB/N versus FVB/N Prnp-/- mouse brains

A search for differentially expressed genes was done by comparison of the expression profiles of FVB/N versus FVB/N Prnp-/- [10, 30] mouse brains. To this aim, RNA samples were prepared by pooling RNAs from 5 brains of 6-week old mice of each genotype. After statistical analysis, two genes were found to be differentially expressed, including the Prnp one (Table 1). The relatively low log ratio observed for the variation in Prnp expression is explained by the fact that the knockout experiment was done in such a way that the gene remains expressed although at a lower level, around 2 to 3 fold, as observed by Northern blotting (data not shown), but that the resulting mRNA does not encode for PrP anymore [10].
Table 1

Candidate genes resulting from microarray studies comparing FVB/N Prnp-/- versus FVB/N mice.


FVB/N Prnp-/-

FVB/N Prnp-/-






(Log2 ratio)








Prion protein or PrPc




Neuroendocrine secretory protein 7B2





Differentially expressed genes detected by the microarray analysis are listed with the calculated differential ratio (log2) alongside the observed delta-delta CT resulting from the QPCR experiment. The comparative Ct method is known as the 2 [delta][delta]Ct method, where delta delta Ct = [delta]Ct, sample - [delta]Ct, reference

QPCR was applied to confirm the suspected differential expression of the detected genes using the same pools of brain RNAs. Both Prnp and Scg5 differential expression were confirmed (Table 1). The higher relative fold-change observed by QPCR for the Prnp gene compared to that detected in the micro-array experiment is related to the location of the used primers in exon 2 and in exon 3 of the PrP-encoding gene respectively, which will not amplify the retro-transcribed RNA expressed by the invalidated locus.

The Scg5 encodes the 7B2 neuroendocrine secretory protein, a specific chaperone for the proprotein convertase 2 [31]. Invalidation of this gene leads to a hypersecretion of cortocitropin that induces early lethality. This protein function was of interest in regards with PrP since hypercorticism is a phenotype associated with scrapie in ewes [32]. However, a search in the mouse genome database for the chromosomal localization of the Prnp and Scg5 loci revealed that these two genes are physically linked and only 11 cM apart. It has been reported that the level of expression of 7B2, at least in the pancreas, differs between mouse strains and is related to a genetic polymorphism that occurs within its proximal promoter [33]. Since the Prnp knockout was done on 129/Sv ES cells, we hypothesized that the Scg5 gene could still be of a 129/Sv genetic origin in FVB/N Prnp-/- mice while it is of FVB/N genetic origin in wild-type mice. We amplified by PCR and sequenced the -200/-60 Scg5 promoter region starting from genomic DNA of three FVB/N, 129/Sv and FVB/N Prnp-/- mice, respectively. A single nucleotide polymorphism (G/T) could be detected at position -97 that discriminates between the FVB/N and the 129/Sv or FVB/N Prnp-/- genotypes (Table 2). These results thus indicate that in the FVB/N Prnp-/- mice, the Scg5 locus remains of 129/Sv genetic origin. It is worth mentioning that the detected single nucleotide polymorphism abolishes a putative AML 1A transcription factor binding site, TGGGGT, in the FVB/N Scg5 promoter possibly explaining the different levels of expression observed. Altogether, these data suggest that the brain Scg5 differential expression between the FVB/N and FVB/N Prnp-/- mice results from a different genetic origin of this locus.
Table 2

Single nucleotide polymorphism observed within the Scg5 proximal promoter region.






FVB/N Prnp -/-




The sequences were obtained from three independent mice of each genotype. The sequences are numbered backward starting from the reported distal-most transcription initiation site [33]. The observed single nucleotide polymorphism is indicated in bold-faced type.

The observed poor transcriptional alteration in the brain of mouse depleted for PrP could suggest that these animals adapted to this genetic environment during embryogenesis. If such, invalidation of the PrP-encoding gene at an adult stage might induce detectable transient modification of the genome transcriptomic regulation. Using already validated conditional knockout transgenic lines [14], we analyzed the potential impact of an adult neuronal PrP depletion on the overall brain transcriptome.

Incidence of a post-natal neuronal PrP depletion on the brain transcriptome

This experiment was performed using Tg37 mice, transgenic mice expressing physiological levels of mouse PrP from a transgene composed of a the floxed coding sequences inserted within the hamster-based CosShaTet expression vector, crossed with NFH-Cre transgenic mice [14]. Both transgenic mice were under a mouse Prnp-knockout genetic background. The brain RNA pools consisted of littermates of 2 males and 2 females of either 10 or 14 weeks old for each Tg37+/- NFH-Cre-/- or Tg37+/- NFH-Cre+/- genotypes. These two ages were chosen since activation of the NFH promoter results in ablation of PrP in neurons after 9 weeks [14]. After statistical analysis, 11 and 47 genes were found to be differentially expressed at 10 (Table 3) or 14 (Table 4) weeks, respectively. At 10 weeks, 3 genes were over-expressed and 8 under-expressed in Prnp depleted mice as compared with the NFH-Cre-negative control animals. At 14 weeks, 21 and 26 genes were over-expressed or under-expressed, respectively. Because the oligonucleotide that recognized Prnp in the microarray is located within the 3' UTR of the gene, a region poorly conserved, it was not expected to detect expression of the Tg37 transgene that encompasses the hamster Prnp 3'UTR sequence and indeed differential expression of this gene was not revealed. The absence of the Scg5 locus within the detected differentially expressed genes further supports the above hypothesis that explains its detection in the previous experiment by a physical link between the Scg5 and the Prnp loci rather than by a functional one.
Table 3

Differentially expressed genes detected at 10 weeks by microarray studies comparing Tg37+/- NFH-Cre-/- and Tg37+/- NFH-Cre+/- brain tissues.

Microarray ID

Locus Name

Ratio (log2)

Bonf Pval

Top Functions





Response to oxidative stress










Cardiovascular system development, Neuronal differentiation





Embryonic Development





Genetic Disorder





Response to oxidative stress





Cell Death, Neurological Disease, Nervous System Development and Function





Cancer, Cell death





Ribosome release





Synaptic vesicle trafficking, Nervous system function, Response to oxidative Stress





Mitochondrial function

Differentially expressed genes detected by the microarray analysis are listed with the calculated differential ratios (log2) and the Bonferroni p values (Bonf Pval). The top functions were deduced either using the Ingenuity pathways analysis software or by looking at the expression pattern and putative functions attributed to those genes (italized annotations). Italic names: genes potentially involved in cellular development and differentiation. Bold-faced type names: genes potentially involved in cell death and disorders, including response to oxidative stress. Italic and bold-faced type names: genes potentially involved in both sets of functions.

Table 4

Differentially expressed genes detected at 14 weeks by microarray studies comparing Tg37+/- NFH-Cre-/- and Tg37+/- NFH-Cre+/- brain tissues.

Microarray ID

Locus Name

Ratio (log2)

Bonf Pval

Top Functions


EST1 (GenebankAV451297.1)



Unknown (Embryonic Development)





DNA replication, Nervous System Development and Function





Eukaryotic polypeptide chain releasing factor










Unknown (Cancer, Cell death)





Cardiovascular Disease, Cellular Development, Embryonic Development





Unknown (Reproductive System)





Unknown (Zinc Finger protein)





Unknown (Embryonic Development)





Unknown (Transmembrane protein)





Cancer, Cardiovascular System Development and Function, Reproductive system Disease





Cardiovascular Disease, Cellular Development, Embryonic Development Cell Death, Neurological Disease, Nervous System





Development and Disease Cell Death, Neurological Disease, Nervous System





Development and Disease





Unknown (expressed in dendtritic cells)





Synaptic vesicle trafficking, Nervous system function, Response to oxidative stress





Unknown (expressed in skin and neonate head)





DNA replication, Nervous System Development and Function





Reproductive System Development and Function





Unknown (Reproductive system)















Cardiovascular Disease, Cellular Development, Embryonic Development





Carbohydrate metabolism, Lipid metabolism, Small molecule Biochemistry





Unknown (Embryonic Development)





Unknown (Nervous System Development)





Synaptic transmission and general secretion










Calcium transport, Response to oxidative stress





Cell Death





DNA replication, Nervous System Development and Function





Cardiovascular Disease, Cellular Development, Embryonic Development





Cardiovascular Disease, Cellular Development, Embryonic Development





Detoxification, Clearance of drugs





Cancer, Cell growth and proliferation, Respiratory Disease





Cell Death, Neurological Disease, Nervous System Development and Disease





Unknown (Reproductive system)





Cardiovascular Disease, Cellular Development, Embryonic Development





Carbohydrate metabolism, Lipid metabolism, Small molecule Biochemistry





DNA replication, Nervous System Development and Function





Neural Development





Embryonic mouse brain development, Neuronal differentiation





Carbohydrate metabolism, Lipid metabolism, Small molecule Biochemistry





Host's innate defense





Cell Death, Neurological Disease, Nervous System Development and Disease





Unknown (Embryonic Development)


GeneBank A530045M11, AI604229, AA174363




Differentially expressed genes detected by the microarray analysis are listed with the calculated differential ratios (log2) and the Bonferroni p values (Bonf Pval). The top functions were deduced either using the Ingenuity pathways analysis software or by looking at the expression pattern and putative functions attributed to those genes (italized annotations). Italic names: genes potentially involved in cellular development and differentiation. Bold-faced type name: gene potentially involved in cell death and disorders, including response to oxidative stress. Italic and bold-faced type names: genes potentially involved in both sets of functions.

QPCR was applied to confirm the microarray results for the genes suspected differentially expressed with the observed highest log2 ratios, using the same pools of brain RNAs and to assess the Cre-induced Prnp invalidation (Table 5). This latter point was confirmed at both 10 and 14 weeks with a highly significant knockdown of the Tg37-transgene expression in the brain of Tg37-NFH-Cre transgenic mice. The down-regulation observed is less important than that detected in FVB/N Prnp-/- mice which is an expected result since the Cre deletion is limited to the neurons, due to the tissue-specificity of the NFH promoter. The slight difference observed between 10 and 14 weeks might suggest that at 10 weeks, the deletion process is not fully complete. The percentage of brain cells that have a deleted Tg37 transgene following Cre activation was previously estimated to be around 29 - 37% [14]. Our data suggest that these cells are among those that express the transgene the most.
Table 5

QPCR analysis of the expression of candidate genes resulting from microarray studies comparing Tg37xNFH-Cre versus Tg37 mice.









(log2 ratio)



10 weeks





glutaredoxin 3




ATPase type 13A1

Prnp Tg37



Prion protein

14 weeks





Hypothetical protein




Interferon-induced transmembrane protein 3




Eukaryote class I release factor




beta-site APP-cleaving enzyme 1





Riken D17







fibroblast growth factor 2

Prnp Tg37



Prion protein

Differentially expressed genes detected by the microarray analysis are listed with the calculated differential ratio (log2) alongside the observed delta-delta CT resulting from the QPCR experiment. The comparative Ct method is known as the 2 - [delta][delta]Ct method, where delta delta Ct = [delta]Ct, sample - [delta]Ct, reference. Age of the analyzed mice is mentioned.

The microarray data were confirmed for 5 out of 9 analyzed genes (Table 5). Among the non-confirmed genes is the above mentioned AV451297.1 putative gene. This gene, located in mouse chromosome 17 and/or mouse chromosome 6, encodes for a hypothetical protein, and its transcription was only reported as an EST in ES cells. The non-confirmation of the differential expression of this gene was surprising since its estimated log ratio was relatively high. Blast alignment of the microarray oligonucleotide corresponding to this gene allowed us to design primers that recognized a family of mouse ESTs that encompass this sequence (Table 6). However, this oligonucleotide aligns with various regions of the mouse genome (data not shown), located on several chromosomes, and we therefore cannot exclude that a transcript, originating from one of these regions, that will not be amplified by our set of primers is responsible for the observed differential expression. Although showing a down-regulated expression in Tg37+/- NFH-Cre+/- mice in both the micro-array analysis and the QPCR experiment, the ratio observed by QPCR was relatively lower than could be expected for the ifitm3 gene. The primers used for the QPCR were chosen in order not to amplify the other ifitm gene family mRNAs (see Table 6 for the QPCR primer sequences). However, they share some homology with the ankyrin repeat domain 12 (data not shown) which might interfere with the obtained results. The other non-confirmed genes correspond to differentially expressed genes showing very low log2 ratios on the microarray results, between -0.8 and + 0.8. Overall the qPCR obtained data for these genes strengthen the relative transcriptomic stability of the Prnp knockout brain. The microarray and QPCR data were consistent for the Erf1 transcriptional deregulation (Table 5). We further analyzed the expression level of this gene in the brain of Prnp-knockout mice expressing or not the NFH-Cre transgene. No difference was observed (data not shown), demonstrating that the Cre expression does not significantly influence the expression profile of this locus and thus that its observed deregulation in our experiment results from the Prnp invalidation. Although we cannot formally exclude that some of the other deregulated genes listed in Tables 3 and 4 results from the Cre expression, this data strongly suggest that the neuronal PrP depletion is responsible for the observed transcriptional modifications.
Table 6

List of the used oligonucleotides

FVB/N PrP-/- mice



SEQUENCE (5' -3')

Prnp 5'


Prnp 3'


scg5 5'


scg5 3'


Tg37xNFH-Cre mice



SEQUENCE (5' -3')

Ifitm3 5'


Ifitm3 3'


AV451297.1 5'


AV451297.1 3'


Erf1 5'


Erf1 3'


Prnp Tg37 5'


Prnp Tg37 3'


Glrx3 5'


Glrx3 3'


Riken D17 5'


Riken D17 3'


Bace1 5'


Bace1 3'


Fgf2 B 5'


Fgf2 B 3'


Atp13a1 5'


Atp13a1 3'


BB217622.2 5'


BB217622.2 3'


β-actin 5'


β-actin 3'


The sequences of the oligonucleotides used in the QPCR experiments are listed; including those of the housekeeping gene that was used in the three described analyses. The sets of primers for the Erf1, Glrx3, BB217622.2 and the AV451297.1 loci were designed within a single exon. All the other sets were designed over exon-exon borders.

The log ratios observed for the other detected differentially expressed genes were relatively low. However, it has to be kept in mind that this invalidation only involved neuronal cells, and probably not all of them [14], and thus that transcriptomic modifications occurring within this cell population will be diluted by the heterogeneous cell composition of the analyzed adult brain tissues. It could also suggest that the biological relevance of the observed variation is doubtful. Only 3 genes were found to be differentially expressed at both stages, Kcnj5, 1810030J14Rik and Synaptotagmin 11 (Tables 3 and 4), of which only 1810030J14Rik was found to behave similarly between these two time-points. This apparent discrepancy could be explained when the function of the differentially express genes was further analyzed, either using the Ingenuity pathways analysis or by looking at the expression pattern and putative functions attributed to those genes (Tables 3 and 4). At 10 weeks, the detected genes appear to reflect a cellular response to an oxidative stress (Table 3), which is in phase with putative physiological functions attributed to PrP [5, 6]. Some of the detected genes also suggest that at that stage, the PrP depletion might induce damaged synaptic trafficking and cell death, two cellular pathways into which PrP is also suspected to have a role (Table 3 and [5, 6]). At 14 weeks, the differentially expressed genes are rather evocative of a remodeling of the nervous system (Table 4). Most of the identified genes are indeed involved in cellular development and neuronal differentiation. The stage-specific modulation of the Kcnj5 and Synaptotagmin II are in agreement with this proposed scenario. So although a few genes are found to be differentially expressed with low detected log ratios, the functions of these genes appear relevant and consistent.

Overall, our data suggest that invalidation of the Prnp gene does not induce gross modification of the adult mouse brain transcriptome. When this event happens a few days before the analysis is performed, we cannot however exclude that the few moderately differentially expressed genes that are then detected indicate a physiological PrP role in adult neuronal homeostasis, synaptic transmission, survival and differentiation. Several hypotheses might explain this unexpected low responsiveness to the invalidation of such an evolutionary conserved protein at least in mammals. An explanation might be that the cellular response to the lack of PrP does not involve transcriptomic alteration but modifications of post-transcriptomic regulations. This latter suggestion is attractive in regards with the recently published miRNA specific signature observed in mouse-scrapie affected brains [34]. However, it is in contradiction with the lack of detectable modification of the brain proteome of Prnp-/- mice [29], which could rather suggest that the variations observed in the miRNA profile is a consequence of the scrapie infection rather than of a PrP loss of function. It is also possible that the overall brain lack of response is due to the fact that the invalidation of the Prnp gene only affects a small subset of the brain cellular population and is therefore not detectable in our present transcriptomic analysis or in the proteomic experiment of Crecelius et al. [29]. Indeed, if as suggested PrP positively regulates neural precursor proliferation in adult [35], the effect of its invalidation might be difficult to assess without prior purification of this cell type. PrP might also be essential for brain response to specific stressful physiological conditions and that the physiological role of this gene was therefore not challenged in the classical presently used breeding conditions. Another attractive explanation would be that PrP has a key function only during early embryogenesis, as its developmental regulation [79] and recently published experimental data involving gene knockdowns [36, 37] suggest. Following this early developmental stage, the physiological role of PrP might be less crucial and/or redundant under normal physiological conditions. If so, it would be important to repeat transcriptomic and proteomic analyses at earlier embryonic stages, at the time Prnp is turned on or under specific breeding conditions.


This paper documents the lack of drastic brain transcriptomic modification following the Prnp invalidation either at the zygotic stage or in adult neuronal cells of the brain tissue. It is consistent with the recently reported proteomic stability of the brain of such PrP-knockout mice [29] and questions some of the obtained results using in vitro cell cultures [2527]. It might suggest that either this gene knockdown affects the animal physiology at a different developmental stage than the one studied here or that it has to be analyzed in certain particular environmental conditions and/or in more specific cell types.


Mouse brain material and DNA or RNA extraction

Mouse brains from five 6 weeks old female FVB/N and FVB/N Prnp -/- animals [10, 30] were collected and frozen in liquid nitrogen immediately after decapitation. Homozygous Tg37 mice were crossed with heterozygous NFH-Cre (Cre 22) mice and the genotype of the resulting pups determined by PCR analysis of their tail-extracted genomic DNA as previously described [14]. Sets of two males and two females of Tg37+/- NFH-Cre+/- or of Tg37+/- NFH-Cre-/- genotype, respectively, and of either 10 or 14 weeks old were obtained and their brains collected and frozen in liquid nitrogen immediately after decapitation. All animal manipulations were done according to the recommendations of the French Commission de Génie Génétique.

RNA extractions for the microarray were made using the RNeasy Lipid Tissue Midi kit (Qiagen cat no. 75842). Each brain sample was treated independently. RNA concentration was calculated by electro-spectrophotometry and the RNA integrity checked with the Agilent Bioanalyser (Waldbroom, Germany). Pools were obtained by mixing equal amounts of total RNA from each individual sample.

Microarray analysis

Microarray analysis was carried out at the Unité de Recherche en Génomique Végétale (URGV, Evry, France) using the mouse 25K array [38] containing 24109 mouse gene-specific oligonucleotides. Amplified RNAs were produced from 2 μg of total RNA from each pool with the "Amino Allyl Message Amp aRNA amplification kit" (Ambion). Five g of amplified RNAs were reversed transcribed with SuperScript II Reverse Transcriptase kit (Invitrogen) in the presence of cy3-dUTP or cy5-dUTP for each slide as previously described [39]. Hybridizations, array scanning and image analyses were performed as previously described [40], using a GenePix 4200A scanner and GenePix Pro 3.0 (Axon Instruments).

The statistical analysis was based on two dye-swap. For each array, the raw data comprised the logarithm of median feature pixel intensity at wavelengths 635 nm (red) and 532 nm (green). No background was subtracted. In the following description, log-ratio refers to the differential expression between the two tissues analyzed: either log2 (red/green) or log2 (green/red), according to the experimental design. An array-by-array normalization was performed to remove systematic biases. First, features that were considered by the experimenter to be badly formed (e.g. because of dust) were excluded (flagged) 100 in the GENEPIX software. Then we performed a global intensity-dependent normalization using the Loess procedure [41] to correct the dye bias. Finally, on each block the log-ratio median was subtracted from each value of the log-ratio of the block to correct a print-tip effect.

To determine differentially expressed genes, we performed a paired t-test. We assumed that the variance of the log-ratios was the same for all genes, by calculating the average of the gene-specific variance. In order to assess this assumption, we excluded spots with a variance too small or too large. Raw P-values were adjusted by the Bonferroni method, which controls the family-wise error rate [42]. A gene is declared differentially expressed if its adjusted P-value is lower than 0.05. The statistical analysis was performed by using the package R anapuce

QPCR analysis

Three μg of purified RNA was reverse transcribed with SuperScript II Reverse Transcriptase kit (Invitrogen) according to the manufacturer's protocol. Quantitative real-time PCR analysis was performed using ABI PRISM 7000 Sequence Detection System (Applied Biosystems) and SYBR Green (Applied Biosystems). Primers used are listed in Table 6. These primers were designed over exon-exon borders if possible. If not, a RT - control was added in the experiment to control for the absence of DNA contaminant. Normalization was done using the β-actin housekeeping gene. The temperature cycle used comprised 45 cycles at 95°C for 15 sec and 60°C for 1 min. A dissociation curve followed, this was comprised of 95°C for 15 sec, 60°C for 1 min and 95°C for 10 sec. Each sample was analysed in triplicate and data analysed using the Delta-Delta Ct method.

Scg5 promoter analysis

Genomic DNA was extracted from tail biopsies as previously described [43]. The Scg5 proximal promoter was amplified by PCR using the set of primers 5'-CCAGGAATCTCCTAAGATCCTGG-3' and 5'-GACATCCTCTAGATTTTAGAATTACC-3' [33]. The amplified DNA fragment was gel purified and sequenced [44].



We are most grateful to John Collinge and colleagues for providing the Tg37 and NFH-Cre transgenic mice and for agreeing to include the data obtained with them in this article and to S. Prusiner for providing the FVB/N Prnp-/- mice. RY is a post-doctorant supported by the French Ministry of Research and the ANR-09-BLAN-OO15-01.

Authors’ Affiliations

INRA, UMR1313, Génétique Animale et Biologie Intégrative, F-78350 Jouy-en-Josas, France
UMR INRA 1165 CNRS 8114, Recherche en Génomique Végétale, UEVE, F-91057 Evry Cedex, France
UMR AgroParisTech/INRA Mathématique et Informatique Appliquées 518, F-75005 Paris, France
INRA, UE 907, Unité Expérimentale Animalerie Rongeur, F-78350 Jouy-en-Josas, France
INRA, UR892, Virologie Immunologie Moléculaires, F-78350 Jouy-en-Josas, France


  1. Aguzzi A, Heikenwalder M, Polymenidou M: Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol. 2007, 8: 552-561. 10.1038/nrm2204.PubMedView ArticleGoogle Scholar
  2. Kovacs GG, Budka H: Molecular pathology of human prion diseases. Int J Mol Sci. 2009, 10: 976-999. 10.3390/ijms10030976.PubMed CentralPubMedView ArticleGoogle Scholar
  3. Prusiner SB: Novel proteinaceous infectious particles cause scrapie. Science. 1982, 216: 136-144. 10.1126/science.6801762.PubMedView ArticleGoogle Scholar
  4. Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY, Kascsak RJ, Cashman NR, Bolton DC: Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology. 1992, 42: 149-156.PubMedView ArticleGoogle Scholar
  5. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR: Physiology of the prion protein. Physiol Rev. 2008, 88: 673-728. 10.1152/physrev.00007.2007.PubMedView ArticleGoogle Scholar
  6. Martins VR, Beraldo FH, Hajj GN, Lopes MH, Lee KS, Prado MM, Linden R: Prion Protein: Orchestrating Neurotrophic Activities. Curr Issues Mol Biol. 2009, 12: 63-86.PubMedGoogle Scholar
  7. Manson J, West JD, Thomson V, McBride P, Kaufman MH, Hope J: The prion protein gene: a role in mouse embryogenesis?. Development. 1992, 115: 117-122.PubMedGoogle Scholar
  8. Miele G, Alejo Blanco AR, Baybutt H, Horvat S, Manson J, Clinton M: Embryonic activation and developmental expression of the murine prion protein gene. Gene Expr. 2003, 11: 1-12. 10.3727/000000003783992324.PubMedView ArticleGoogle Scholar
  9. Tremblay P, Bouzamondo-Bernstein E, Heinrich C, Prusiner SB, DeArmond SJ: Developmental expression of PrP in the post-implantation embryo. Brain Res. 2007, 1139: 60-67. 10.1016/j.brainres.2006.12.055.PubMed CentralPubMedView ArticleGoogle Scholar
  10. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner SB, Aguet M, Weissmann C: Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992, 356: 577-582. 10.1038/356577a0.PubMedView ArticleGoogle Scholar
  11. Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J: 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol. 1994, 8: 121-127. 10.1007/BF02780662.PubMedView ArticleGoogle Scholar
  12. Richt JA, Kasinathan P, Hamir AN, Castilla J, Sathiyaseelan T, Vargas F, Sathiyaseelan J, Wu H, Matsushita H, Koster J: Production of cattle lacking prion protein. Nat Biotechnol. 2007, 25: 132-138. 10.1038/nbt1271.PubMed CentralPubMedView ArticleGoogle Scholar
  13. Yu G, Chen J, Xu Y, Zhu C, Yu H, Liu S, Sha H, Chen J, Xu X, Wu Y: Generation of goats lacking prion protein. Mol Reprod Dev. 2009, 76: 3-10.1002/mrd.20960.PubMedView ArticleGoogle Scholar
  14. Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, Jefferys JG, Collinge J: Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. Embo J. 2002, 21: 202-210. 10.1093/emboj/21.3.202.PubMed CentralPubMedView ArticleGoogle Scholar
  15. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR: Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA. 2008, 105: 10238-10243. 10.1073/pnas.0802759105.PubMed CentralPubMedView ArticleGoogle Scholar
  16. Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Gotz J, Rulicke T, Flechsig E, Cozzio A, von Mering C: Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell. 1998, 93: 203-214. 10.1016/S0092-8674(00)81572-X.PubMedView ArticleGoogle Scholar
  17. Xiang W, Windl O, Wunsch G, Dugas M, Kohlmann A, Dierkes N, Westner IM, Kretzschmar HA: Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J Virol. 2004, 78: 11051-11060. 10.1128/JVI.78.20.11051-11060.2004.PubMed CentralPubMedView ArticleGoogle Scholar
  18. Brown AR, Rebus S, McKimmie CS, Robertson K, Williams A, Fazakerley JK: Gene expression profiling of the preclinical scrapie-infected hippocampus. Biochem Biophys Res Commun. 2005, 334: 86-95. 10.1016/j.bbrc.2005.06.060.PubMedView ArticleGoogle Scholar
  19. Skinner PJ, Abbassi H, Chesebro B, Race RE, Reilly C, Haase AT: Gene expression alterations in brains of mice infected with three strains of scrapie. BMC Genomics. 2006, 7: 114-10.1186/1471-2164-7-114.PubMed CentralPubMedView ArticleGoogle Scholar
  20. Xiang W, Hummel M, Mitteregger G, Pace C, Windl O, Mansmann U, Kretzschmar HA: Transcriptome analysis reveals altered cholesterol metabolism during the neurodegeneration in mouse scrapie model. J Neurochem. 2007, 102: 834-847. 10.1111/j.1471-4159.2007.04566.x.PubMedView ArticleGoogle Scholar
  21. Sorensen G, Medina S, Parchaliuk D, Phillipson C, Robertson C, Booth SA: Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. BMC Genomics. 2008, 9: 114-10.1186/1471-2164-9-114.PubMed CentralPubMedView ArticleGoogle Scholar
  22. Julius C, Hutter G, Wagner U, Seeger H, Kana V, Kranich J, Klohn PC, Weissmann C, Miele G, Aguzzi A: Transcriptional stability of cultured cells upon prion infection. J Mol Biol. 2008, 375: 1222-1233. 10.1016/j.jmb.2007.11.003.PubMedView ArticleGoogle Scholar
  23. Miele G, Seeger H, Marino D, Eberhard R, Heikenwalder M, Stoeck K, Basagni M, Knight R, Green A, Chianini F: Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS One. 2008, 3: e3870-10.1371/journal.pone.0003870.PubMed CentralPubMedView ArticleGoogle Scholar
  24. Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, Baxter D, Pitstick R, Young R, Spicer D: A systems approach to prion disease. Mol Syst Biol. 2009, 5: 252-10.1038/msb.2009.10.PubMed CentralPubMedView ArticleGoogle Scholar
  25. Liang J, Luo G, Ning X, Shi Y, Zhai H, Sun S, Jin H, Liu Z, Zhang F, Lu Y: Differential expression of calcium-related genes in gastric cancer cells transfected with cellular prion protein. Biochem Cell Biol. 2007, 85: 375-383. 10.1139/O07-052.PubMedView ArticleGoogle Scholar
  26. Satoh J, Yamamura T: Gene expression profile following stable expression of the cellular prion protein. Cell Mol Neurobiol. 2004, 24: 793-814. 10.1007/s10571-004-6920-0.PubMedView ArticleGoogle Scholar
  27. Satoh J, Kuroda Y, Katamine S: Gene expression profile in prion protein-deficient fibroblasts in culture. Am J Pathol. 2000, 157: 59-68.PubMed CentralPubMedView ArticleGoogle Scholar
  28. Ramljak S, Asif AR, Armstrong VW, Wrede A, Groschup MH, Buschmann A, Schulz-Schaeffer W, Bodemer W, Zerr I: Physiological role of the cellular prion protein (PrPc): protein profiling study in two cell culture systems. J Proteome Res. 2008, 7: 2681-2695. 10.1021/pr7007187.PubMedView ArticleGoogle Scholar
  29. Crecelius AC, Helmstetter D, Strangmann J, Mitteregger G, Frohlich T, Arnold GJ, Kretzschmar HA: The brain proteome profile is highly conserved between Prnp-/- and Prnp+/+ mice. Neuroreport. 2008, 19: 1027-1031. 10.1097/WNR.0b013e3283046157.PubMedView ArticleGoogle Scholar
  30. Giri RK, Young R, Pitstick R, DeArmond SJ, Prusiner SB, Carlson GA: Prion infection of mouse neurospheres. Proc Natl Acad Sci USA. 2006, 103: 3875-3880. 10.1073/pnas.0510902103.PubMed CentralPubMedView ArticleGoogle Scholar
  31. Mbikay M, Seidah NG, Chretien M: Neuroendocrine secretory protein 7B2: structure, expression and functions. Biochem J. 2001, 357: 329-342. 10.1042/0264-6021:3570329.PubMed CentralPubMedView ArticleGoogle Scholar
  32. Gayrard V, Picard-Hagen N, Grino M, Sauze N, Grandjean C, Galea J, Andreoletti O, Schelcher F, Toutain PL: Major hypercorticism is an endocrine feature of ewes with naturally occurring scrapie. Endocrinology. 2000, 141: 988-994. 10.1210/en.141.3.988.PubMedView ArticleGoogle Scholar
  33. Schmidt G, Sirois F, Anini Y, Kauri LM, Gyamera-Acheampong C, Fleck E, Scott FW, Chretien M, Mbikay M: Differences of pancreatic expression of 7B2 between C57BL/6J and C3H/HeJ mice and genetic polymorphisms at its locus (Sgne1). Diabetes. 2006, 55: 452-459. 10.2337/diabetes.55.02.06.db05-0733.PubMedView ArticleGoogle Scholar
  34. Saba R, Goodman CD, Huzarewich RL, Robertson C, Booth SA: A miRNA signature of prion induced neurodegeneration. PLoS One. 2008, 3: e3652-10.1371/journal.pone.0003652.PubMed CentralPubMedView ArticleGoogle Scholar
  35. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD: Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci USA. 2006, 103: 3416-3421. 10.1073/pnas.0511290103.PubMed CentralPubMedView ArticleGoogle Scholar
  36. Malaga-Trillo E, Solis GP, Schrock Y, Geiss C, Luncz L, Thomanetz V, Stuermer CA: Regulation of embryonic cell adhesion by the prion protein. PLoS Biol. 2009, 7: e55-10.1371/journal.pbio.1000055.PubMedView ArticleGoogle Scholar
  37. Young R, Passet B, Vilotte M, Cribiu EP, Beringue V, Le Provost F, Laude H, Vilotte JL: The prion or the related Shadoo protein is required for early mouse embryogenesis. FEBS Lett. 2009, 583: 3296-3300. 10.1016/j.febslet.2009.09.027.PubMedView ArticleGoogle Scholar
  38. Le Brigand K, Russell R, Moreilhon C, Rouillard JM, Jost B, Amiot F, Magnone V, Bole-Feysot C, Rostagno P, Virolle V: An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomes. Nucleic Acids Res. 2006, 34: e87-10.1093/nar/gkl485.PubMedView ArticleGoogle Scholar
  39. Lurin C, Andres C, Aubourg S, Bellaoui M, Bitton F, Bruyere C, Caboche M, Debast C, Gualberto J, Hoffmann B: Genome-wide analysis of Arabidopsis pentatricopeptide repeat proteins reveals their essential role in organelle biogenesis. Plant Cell. 2004, 16: 2089-2103. 10.1105/tpc.104.022236.PubMed CentralPubMedView ArticleGoogle Scholar
  40. Minic Z, Jamet E, San-Clemente H, Pelletier S, Renou JP, Rihouey C, Okinyo DP, Proux C, Lerouge P, Jouanin L: Transcriptomic analysis of Arabidopsis developing stems: a close-up on cell wall genes. BMC Plant Biol. 2009, 9: 6-10.1186/1471-2229-9-6.PubMed CentralPubMedView ArticleGoogle Scholar
  41. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002, 30: e15-10.1093/nar/30.4.e15.PubMed CentralPubMedView ArticleGoogle Scholar
  42. Ge X, Tsutsumi S, Aburatani H, Iwata S: Reducing false positives in molecular pattern recognition. Genome Inform. 2003, 14: 34-43.PubMedGoogle Scholar
  43. Vilotte JL, Soulier S, Stinnakre MG, Massoud M, Mercier JC: Efficient tissue-specific expression of bovine alpha-lactalbumin in transgenic mice. Eur J Biochem. 1989, 186: 43-48. 10.1111/j.1432-1033.1989.tb15175.x.PubMedView ArticleGoogle Scholar
  44. Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, Hutchison CA, Slocombe PM, Smith M: Nucleotide sequence of bacteriophage phi X174 DNA. Nature. 1977, 265: 687-695. 10.1038/265687a0.PubMedView ArticleGoogle Scholar


© Chadi et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.